<DOC>
	<DOCNO>NCT02422615</DOCNO>
	<brief_summary>This multi-center , randomize , double-blinded , placebo control trial men post-menopausal woman advance breast cancer .</brief_summary>
	<brief_title>Study Efficacy Safety LEE011 Men Postmenopausal Women With Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Patient adult male/female ≥ 18 year old time inform consent sign informed consent trial related activity accord local guideline . Female patient must postmenopausal . 2 . Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer local laboratory HER2negative breast cancer . 3 . Patient must either measurable disease RECIST 1.1 least one predominantly lytic bone lesion . 4 . Patient advance ( loco regionally recurrent amenable curative therapy , e.g . surgery and/or radiotherapy , metastatic ) breast cancer . Patients may : newly diagnose advanced/metastatic breast cancer , treatment naïve relapse documented evidence relapse 12 month completion ( neo ) adjuvant endocrine therapy treatment advanced/metastatic disease relapse documented evidence relapse within 12 month completion ( neo ) adjuvant endocrine therapy treatment advanced/metastatic disease relapse documented evidence relapse 12 month completion adjuvant endocrine therapy subsequently progress documented evidence progression one line endocrine therapy ( either antiestrogen aromatase inhibitor ) advanced/metastatic disease newly diagnose advanced/metastatic breast cancer diagnosis progress documented evidence progression one line endocrine therapy ( either antiestrogen aromatase inhibitor ) 5 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 6 . Patient adequate bone marrow organ function 1 . Patient symptomatic visceral disease disease burden make patient ineligible endocrine therapy per investigator 's best judgment . 2 . Patient receive prior treatment chemotherapy ( except neoadjuvant/ adjuvant chemotherapy ) , fulvestrant CDK4/6 inhibitor . 3 . Patient inflammatory breast cancer screen . 4 . Patient CNS involvement unless least 4 week prior therapy completion start study treatment stable CNS tumor time screen receive steroid and/or enzyme induce antiepileptic medication brain metastases 5 . Clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality 6 . Patient currently receive follow substance discontinue 7 day prior start treatment : Known strong inducer inhibitor CYP3A4/5 , That know risk prolong QT interval induce Torsades de Pointes . Those narrow therapeutic window predominantly metabolize CYP3A4/5 . Herbal preparations/medications , dietary supplement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>ribociclib</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>faslodex</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>CDK4/6 inhibitor</keyword>
	<keyword>Phase III</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Men</keyword>
</DOC>